Perrigo Company plc (NYSE:PRGO) Receives Average Rating of “Hold” from Brokerages

Shares of Perrigo Company plc (NYSE:PRGO) have been given an average rating of “Hold” by the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $19.3333.

Several research firms recently issued reports on PRGO. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th.

Perrigo Stock Up 24.1%

Shares of NYSE PRGO opened at $13.37 on Thursday. Perrigo has a 12-month low of $9.23 and a 12-month high of $24.60. The firm’s 50-day simple moving average is $10.56 and its 200 day simple moving average is $11.55. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -1.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.51.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business earned ($0.06) earnings per share. Perrigo’s quarterly revenue was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts expect that Perrigo will post 2.09 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 8.7%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio is currently -8.85%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PRGO. Price T Rowe Associates Inc. MD boosted its holdings in Perrigo by 3.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock worth $244,634,000 after buying an additional 653,925 shares during the last quarter. Vanguard Group Inc. boosted its stake in Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after acquiring an additional 1,101,154 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in Perrigo by 291.9% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after purchasing an additional 5,828,076 shares during the period. State Street Corp raised its holdings in Perrigo by 9.5% in the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after purchasing an additional 637,678 shares during the period. Finally, Thompson Siegel & Walmsley LLC boosted its position in shares of Perrigo by 28.4% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock worth $64,848,000 after purchasing an additional 1,029,770 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Quarterly earnings surpassed expectations. Perrigo reported adjusted EPS of approximately $0.50, above the $0.31-$0.34 analyst estimates and ahead of the $0.57 earned a year earlier on a comparable basis. Revenue of about $1.02 billion also exceeded the roughly $1.01 billion consensus estimate. Perrigo Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year EPS guidance is above consensus. Perrigo provided FY 2026 EPS guidance of $2.25-$2.55, compared with the analyst consensus of $2.11, while reaffirming expectations for stronger performance in the second half of the year. Revenue guidance of $4.0-$4.2 billion broadly surrounds the $4.1 billion consensus estimate. Perrigo Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management highlighted operational progress. Perrigo cited market-share gains in U.S. store-brand over-the-counter products and key European brands, completed its Dermacosmetics divestiture, and continued efforts to streamline the portfolio and reduce debt. Infant Formula sales rose 23.1%, helped by contract-shipment timing and higher store-brand sales. Perrigo Second Quarter Results
• Negative Sentiment: Sales declined year over year. Second-quarter net sales fell about 3.1%-3.2% to $1.02 billion, while core organic sales declined 3.5%. Perrigo also pointed to category softness and macroeconomic headwinds, indicating that the earnings improvement has not yet translated into broad-based revenue growth. Perrigo Q2 Net Sales Fall
• Neutral Sentiment: Portfolio reviews remain a catalyst and uncertainty. Strategic reviews of the Infant Formula and Oral Care businesses could lead to additional streamlining, but the eventual impact on revenue and earnings is not yet clear.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.